New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 29, 2012
13:55 EDTBAX, BAX, BAYRY, BAYRY, BIIB, BIIB, PBTH, PBTH, NVO, NVOLeerink's biotech analyst holds an analyst/industry conference call
Biotech Analyst Schimmer discusses the outlook for long-acting factor replacements in hemophilia on an Analyst/Industry conference call. Relevant covered companies BAX, BAYRY, BIIB, PBTH and NVO may be included on the Analyst/Industry conference call to be held on March 29 at 2 pm.
News For BAX;BAYRY;BIIB;PBTH;NVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
10:58 EDTBIIBDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
09:05 EDTBAXBaxter files for European approval of investigational IGSC 20% treatment for PI
Baxter International announced that its BioScience business has submitted a marketing authorization application to 17 competent authorities in Europe following the decentralized procedure for approval of its investigational 20% concentration subcutaneous immune globulin, or IGSC, treatment for primary immunodeficiencies, or PI, a group of disorders in which part of the body's immune system is missing or does not function properly. Results from a separate study of IGSC 20% among patients with PI in North America are expected to be available in the coming months; based on the outcome of this study, Baxter intends to file for U.S. approval of the treatment before the end of 2015.
06:38 EDTNVO, BAXNovo Nordisk rejects claims made by Baxter, Reuters says
Novo Nordisk (NVO) rejects claims made by Baxter (BAX) that the company used substances made by Baxter in its Novoeight haemophilia treatment, following Monday's ITC investigation announcement, reports Reuters, citing an email from Novo Nordisk. Reference Link
May 20, 2015
10:26 EDTNVOJanssen acquires licence from Novo Nordisk for autoimmune disease development
Novo Nordisk (NVO) announced it has signed an agreement with Janssen Biotech (JNJ) under which Janssen will acquire an exclusive global license to further develop and commercialize a clinical program focused on therapy within autoimmune diseases. The program targets modulation of certain immune cells via a cell surface receptor, specifically the NKG2D receptor. Terms of the agreement have not been disclosed.
May 18, 2015
12:24 EDTBAXBaxter sees FY16 sales growth 2%-3%
Subscribe for More Information
12:20 EDTBAXBaxter sees 2H sales growth approximately flat in constant currency
Subscribe for More Information
08:39 EDTBAXBaxter says Baxalta separation on-track for mid-year 2015
Subscribe for More Information
May 15, 2015
17:31 EDTBAXBaxter gets FDA approval for Spain facility to produce Sodium Chloride Injection
Subscribe for More Information
10:29 EDTBAYRYAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTBAYRY, BIIBAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
07:26 EDTBAYRYBayer expecting crops and seeds industry consolidation, Reuters reports
Subscribe for More Information
May 14, 2015
14:54 EDTBAYRYJohnson & Johnson unit reports results of VENTURE-AF trial
Subscribe for More Information
May 13, 2015
18:43 EDTBAYRYBayer to present Xofigo, ODM-201 data at 2015 ASCO meeting
Subscribe for More Information
10:40 EDTBAXBaxter to host two day investor meeting
Two day Investor meeting to be held in New York May 18-19.
07:32 EDTBIIBBiogen names Matt Griffiths as CIO
Subscribe for More Information
May 12, 2015
09:02 EDTBAXBaxter expects to establish BioScience business as separate business by mid-year
Subscribe for More Information
09:01 EDTBAXBaxter to acquire Oncaspar product portfolio from Sigma-Tau for $900M
Subscribe for More Information
07:06 EDTBAXKamada sees FY15 revenue $70M-$73M, consensus $78.69M
Kamada (KMDA) sees revenue from its Distributed Product Segment projected to be between $26 million and $28 million and revenue from its Proprietary Products Segment projected to be between $45 million and $47 million. The company notes that revenue projections for 2015 take into account an expected negative foreign exchange impact of approximately $2.0 million in relation to product sales in Israel and Russia, and presume that U.S. revenue from the agreement with Baxter (BAX) remains on track.
May 8, 2015
17:22 EDTBAYRYBayer sends letter to NY Times regarding Essure story
Subscribe for More Information
14:11 EDTBAYRYFDA approves Bayer plague treaatment Avelox
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use